作者
Chao Liang,Baosheng Guo,Heng Wu,Ningsheng Shao,Defang Li,Jin Liu,Lei Dang,Cheng Wang,Hui Li,Shaohua Li,Wing Ki Lau,Yu Cao,Zhijun Yang,Cheng Lü,Xiaojuan He,Doris W.T. Au,Xiaohua Pan,Bao‐Ting Zhang,Changwei Lu,Hongqi Zhang,Kevin K.M. Yue,Airong Qian,Peng Shang,Jiake Xu,Lianbo Xiao,Zhaoxiang Bian,Weihong Tan,Zicai Liang,Fuchu He,Lingqiang Zhang,Aiping Lü,Ge Zhang
摘要
Currently, major concerns about the safety and efficacy of RNA interference (RNAi)-based bone anabolic strategies still exist because of the lack of direct osteoblast-specific delivery systems for osteogenic siRNAs. Here we screened the aptamer CH6 by cell-SELEX, specifically targeting both rat and human osteoblasts, and then we developed CH6 aptamer-functionalized lipid nanoparticles (LNPs) encapsulating osteogenic pleckstrin homology domain-containing family O member 1 (Plekho1) siRNA (CH6-LNPs-siRNA). Our results showed that CH6 facilitated in vitro osteoblast-selective uptake of Plekho1 siRNA, mainly via macropinocytosis, and boosted in vivo osteoblast-specific Plekho1 gene silencing, which promoted bone formation, improved bone microarchitecture, increased bone mass and enhanced mechanical properties in both osteopenic and healthy rodents. These results indicate that osteoblast-specific aptamer-functionalized LNPs could act as a new RNAi-based bone anabolic strategy, advancing the targeted delivery selectivity of osteogenic siRNAs from the tissue level to the cellular level.